Key result
Etizolam inhibited PAF-induced aggregation in rabbit platelets with an IC50 of 3.8 microM and specific binding to PAF receptors with an IC50 of 22 nM, indicating it is a specific PAF antagonist.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications from in vitro data; leaves open etizolam’s role as PAF antagonist in cardiovascular research.
The antagonistic effect of etizolam, an anti-anxiety drug, on platelet-activating factor (PAF) was investigated in rabbit platelets in vitro. Etizolam inhibited PAF-induced aggregation in a dose-dependent manner, with an IC50 of 3.8 microM, about one tenth that of triazolam (IC50 = 30 microM). At 300 microM, it inhibited both ADP and arachidonic acid-induced aggregation only slightly, while the other anti-anxiety drugs tested had no effect on PAF-induced aggregation even at this concentration. Etizolam and triazolam inhibited the specific binding of 3H-PAF to PAF receptor sites on washed rabbit platelets with IC50 values of 22 nM and 320 nM, respectively. Diazepam and estazolam were inactive even at 1 microM. These results indicate that etizolam is a specific antagonist of PAF.
No takes yet. Share an insight, caveat, or question.
Mikashima et al. (1987) studied this question. Etizolam vs. Triazolam, diazepam, estazolam was evaluated on PAF-induced aggregation and specific binding of 3H-PAF to PAF receptor sites. Etizolam inhibited PAF-induced aggregation in rabbit platelets with an IC50 of 3.8 microM and specific binding to PAF receptors with an IC50 of 22 nM, indicating it is a specific PAF antagonist.
Synapse has enriched 10 related papers. Consider them for comparative context: